@article {8501,
	title = {{Androgens In Men Study (AIMS): protocol for meta-analyses of individual participant data investigating associations of androgens with health outcomes in men},
	journal = {BMJ Open},
	volume = {10},
	year = {2020},
	month = {05},
	pages = {e034777},
	abstract = {This study aims to clarify the role(s) of endogenous sex hormones to influence health outcomes in men, specifically to define the associations of plasma testosterone with incidence of cardiovascular events, cancer, dementia and mortality risk, and to identify factors predicting testosterone concentrations. Data will be accrued from at least three Australian, two European and four North American population-based cohorts involving approximately 20 000 men.\ Eligible studies include prospective cohort studies with baseline testosterone concentrations measured using mass spectrometry and 5 years of follow-up data on incident cardiovascular events, mortality, cancer diagnoses or deaths, new-onset dementia or decline in cognitive function recorded. Data for men, who were not taking androgens or drugs suppressing testosterone production, metabolism or action; and had no prior orchidectomy, are eligible. Systematic literature searches were conducted from 14 June 2019 to 31 December 2019, with no date range set for searches. Aggregate level data will be sought where individual participant data (IPD) are not available. One-stage IPD random-effects meta-analyses will be performed, using linear mixed models, generalised linear mixed models and either stratified or frailty-augmented Cox regression models. Heterogeneity in estimates from different studies will be quantified and bias investigated using funnel plots. Effect size estimates will be presented in forest plots and non-negligible heterogeneity and bias investigated using subgroup or meta-regression analyses.\ Ethics approvals obtained for each of the participating cohorts state that participants have consented to have their data collected and used for research purposes. The Androgens In Men Study has been assessed as exempt from ethics review by the Human Ethics office at the University of Western Australia (file reference number RA/4/20/5014). Each of the component studies had obtained ethics approvals; please refer to respective component studies for details. Research findings will be disseminated to the scientific and broader community via the publication of four research articles, with each involving a separate set of IPD meta-analyses (articles will investigate different, distinct outcomes), at scientific conferences and meetings of relevant professional societies. Collaborating cohort studies will disseminate findings to study participants and local communities.\ CRD42019139668.},
	author = {Yeap, B. B. and Marriott, R. J. and Adams, R. J. and Antonio, L. and Ballantyne, C. M. and Bhasin, S. and Cawthon, P. M. and Couper, D. J. and Dobs, A. S. and Flicker, L. and Karlsson, M. and Martin, S. A. and Matsumoto, A. M. and Mellstr?m, D. and Norman, P. E. and Ohlsson, C. and Orwoll, E. S. and O{\textquoteright}Neill, T. W. and Shores, M. M. and Travison, T. G. and Vanderschueren, D. and Wittert, G. A. and Wu, F. C. W. and Murray, K.}
}
@article {8638,
	title = {{An individual participant data analysis of prospective cohort studies on the association between subclinical thyroid dysfunction and depressive symptoms},
	journal = {Sci Rep},
	volume = {10},
	year = {2020},
	month = {11},
	pages = {19111},
	abstract = {{In subclinical hypothyroidism, the presence of depressive symptoms is often a reason for starting levothyroxine treatment. However, data are conflicting on the association between subclinical thyroid dysfunction and depressive symptoms. We aimed to examine the association between subclinical thyroid dysfunction and depressive symptoms in all prospective cohorts with relevant data available. We performed a systematic review of the literature from Medline, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Library from inception to 10th May 2019. We included prospective cohorts with data on thyroid status at baseline and depressive symptoms during follow-up. The primary outcome was depressive symptoms measured at first available follow-up, expressed on the Beck{\textquoteright}s Depression Inventory (BDI) scale (range 0-63, higher values indicate more depressive symptoms, minimal clinically important difference: 5 points). We performed a two-stage individual participant data (IPD) analysis comparing participants with subclinical hypo- or hyperthyroidism versus euthyroidism, adjusting for depressive symptoms at baseline, age, sex, education, and income (PROSPERO CRD42018091627). Six cohorts met the inclusion criteria, with IPD on 23,038 participants. Their mean age was 60 years, 65\% were female, 21,025 were euthyroid, 1342 had subclinical hypothyroidism and 671 subclinical hyperthyroidism. At first available follow-up [mean 8.2 ({\^A}{\textpm} 4.3) years], BDI scores did not differ between participants with subclinical hypothyroidism (mean difference = 0.29, 95\% confidence interval = - 0.17 to 0.76},
	author = {Wildisen, L. and Del Giovane, C. and Moutzouri, E. and Beglinger, S. and Syrogiannouli, L. and Collet, T. H. and Cappola, A. R. and ?svold, B. O. and Bakker, S. J. L. and Yeap, B. B. and Almeida, O. P. and Ceresini, G. and Dullaart, R. P. F. and Ferrucci, L. and Grabe, H. and Jukema, J. W. and Nauck, M. and Trompet, S. and V?lzke, H. and Westendorp, R. and Gussekloo, J. and Kl?ppel, S. and Aujesky, D. and Bauer, D. and Peeters, R. and Feller, M. and Rodondi, N.}
}
